- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Malvern Today
By the People, for the People
HC Wainwright Brokers Increase Earnings Estimates for Ocugen
Analysts raise Q1 2026 earnings per share estimates for the biopharmaceutical company.
Mar. 11, 2026 at 11:44am
Got story updates? Submit your updates here. ›
Analysts at HC Wainwright have increased their Q1 2026 earnings per share estimates for Ocugen, Inc. (NASDAQ:OCGN), a clinical-stage biopharmaceutical company focused on gene therapies for rare inherited retinal diseases and vaccines for infectious diseases. The analysts now expect Ocugen to post earnings per share of ($0.06) for the quarter, up from their previous estimate of ($0.07).
Why it matters
Ocugen is a small but promising biotech company working on innovative treatments in the gene therapy and vaccine spaces. Positive earnings revisions from respected analysts like HC Wainwright could signal growing confidence in Ocugen's pipeline and future prospects, which could boost investor interest and the company's stock price.
The details
In their research report, HC Wainwright analyst S. Ramakanth also increased estimates for Ocugen's earnings in subsequent quarters and full years through 2029. The consensus estimate for Ocugen's current full-year earnings is ($0.20) per share. Ocugen last reported earnings on March 4th, posting a loss of $0.06 per share on revenue of ($0.19) million.
- Ocugen reported Q1 2026 earnings estimates on March 9, 2026.
- Ocugen last reported earnings on March 4, 2026.
The players
HC Wainwright
An investment banking and securities firm that provides research coverage and other services for Ocugen.
S. Ramakanth
An analyst at HC Wainwright who covers Ocugen and issued the revised earnings estimates.
Ocugen, Inc.
A clinical-stage biopharmaceutical company focused on gene therapies for rare inherited retinal diseases and vaccines for infectious diseases.
What they’re saying
“HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of ($0.06) for the quarter, up from their previous estimate of ($0.07).”
— S. Ramakanth, Analyst (HC Wainwright)
The takeaway
Positive earnings revisions from respected analysts like HC Wainwright suggest growing confidence in Ocugen's pipeline and future prospects, which could boost investor interest and the company's stock price as it continues to advance its innovative gene therapy and vaccine programs.
